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Received July 21, 2012; accepted January 14, 2013AbstractBackground: Adenosquamous carcinoma (ASC) of the lung is a rare subtype of nonsmall-cell lung cancer (NSCLC). To date, the efficacious
targeted therapy for advanced ASC remains unclear and the epidermal growth factor receptor (EGFR) mutation rate is not well known.
Methods: We retrospectively reviewed clinical information of patients with ASC who were treated with gefitinib or erlotinib at Zhejiang Cancer
Hospital between January 2007 and December 2011. Survival analysis was evaluated by the Kaplan-Meier method. EGFR mutations were
assessed in part using direct sequencing methods.
Results: In total, 49 patients with a median age of 57 years were used in this study. Thirteen patients achieved a partial response and 19 had
disease stabilization. The objective response rate was 26.5%, and the disease control rate was 65.3%. The median progression-free survival and
overall survival were 4.3 and 17.6 months, respectively. In 21 patients with adequate specimens for molecular analysis, 7 (33.3%) had EGFR
mutations (4 with deletions within exon 19 and 3 with L858R messenger mutation in exon 21). EGFR mutations were significantly more
frequent in women (4/9, 44.4%) than men (3/12, 25%), never-smokers (6/15, 40%), and smokers (1/6, 16.7%).
Conclusion: EGFR-tyrosine kinase inhibitor (TKI) is an effective treatment for ASC. The frequency of EGFR mutation and clinical charac-
teristics of the EGFR mutants in ASC are similar to those of Asian patients with adenocarcinoma.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Adenocarcinoma and squamous cell carcinoma (SCC) are
two major subtypes of NSCLC. Adenosquamous carcinoma
(ASC) is a rare subtype of NSCLC, comprising 0.4e4% of
pulmonary carcinomas.1e4 ASC is a mixed histologic tumor;
according to the last WHO lung tumor classification criteria, it
is defined as “a carcinoma showing components of both
squamous cell carcinoma and adenocarcinoma, with each
comprising to at least 10% of the tumor”.5 A clinicopatho-
logical analysis has demonstrated that ASC is more aggressive
than adenocarcinoma and SCC, indicating that its biological
features are different from these types of NSCLC.6e8 The* Corresponding author. Dr. Yiping Zhang, Department of Chemotherapy,
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http://dx.doi.org/10.1016/j.jcma.2013.05.007epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs) including gefitinib and erlotinib are the primary
drugs of choice for the treatment of NSCLC patients, espe-
cially for the patients harboring EGFR mutations.9,10 How-
ever, no clinical study to evaluate efficacy of EGFR-TKIs and
mutation frequency for ASC has been conducted thus far.
We conducted a focused analysis targeting Chinese pop-
ulations in order to track the EGFR mutation status of ASC, as
well as to check the feasibility of EGFR-TKIs treatment in ASC.2. Methods2.1. PatientsA retrospective review of patients from the Zhejiang
Cancer Hospital between January 2007 and December 2011hinese Medical Association. All rights reserved.
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Hospital approved the study. NSCLC staging was performed
according to the 7th TNM classification. The inclusion criteria
were as follows: (1) pathologically proven primary ASC, (2)
all patients were supplied with TKI during the treatment
course, (3) disease recurrence was confirmed using chest
computed tomography (CT), brain MRI and bone scan as well
as ultrasound examination and/or CT of the abdomen, (4)
without any local treatment such as radiotherapy or interven-
tional therapy during the period of TKI therapy, and (5) at
least one measurable lesion and an Eastern Cooperative
Oncology Group performance status of 0 to 3.2.2. Pathology and EGFR mutation examination methodTo confirm the histology of ASC, each of the slides pre-
viously identified was examined independently by two spe-
cialists according to the World Health Organization criteria
(2004 version). The molecular analysis of EGFR was per-
formed using direct sequencing methods with formalin-fixed
paraffin embedded archival tissue blocks. Additionally,
EGFR mutation analysis using direct sequencing occurred as
previously described.11 Briefly, DNA was extracted from the
tumors using a QIAmp DNA Mini kit (Qiagen, Hilden,
Germany) following the manufacturer’s protocols. The tyro-
sine kinase domain of the EGFR coding sequences were
analyzed by Sequencer 3.1.1. software (Applied Biosystems)
to compare variations. Exons 18-21 of EGFR were then
examined.2.3. Responses and toxicityTumor responses were assessed with computed tomography
(CT) at 4e8-week intervals until the lesions were evaluated as
the progressive disease. The tumor response was evaluated
based on the Response Evaluation Criteria in Solid Tumor
(RECIST) version 1.1. Objective tumor responses include
complete response (CR), partial response (PR), stable disease
(SD), and progressive disease (PD). Objective response
included the CR and PR. Disease control rate (DCR) was
defined as the addition of objective response and stabilization
rates (CR þ PR þ SD).
The toxicity of TKI treatment was evaluated in accordance
with the National Cancer Institute Common Toxicity Criteria
(NCI-CTC) version 3.0.2.4. Follow-upAll patients that were evaluated for the TKI tumor response
had a progression-free survival (PFS), and none of the patients
were lost to follow-up. The median follow-up period was 20.2
months (3.9-52); the last follow-up time was January 30, 2012.2.5. Statistical analysisCategorical variables were compared using the c2 test and
continuous variables by the Mann-Whitney nonparametrictest. Survival was recorded from the first-line of treatment to
the date of death or that of the last follow-up visit. The PFS
encompassed the time from the TKI therapy to documented
progression or death from any cause. The survival curves were
calculated according to the method of Kaplan-Meier. The Cox
proportional model was used to evaluate various prognostic
factors. Values of p < 0.05 were considered significant. An-
alyses were conducted using the computer software SPSS
version 16.0 (SPSS Inc., Chicago, IL, USA).
3. Results3.1. Patient characteristicsOverall, 1679 patients were diagnosed with primary
NSCLC between January 2007 and December 2011. Of these,
975 had advanced disease or recurrence after surgery. TKI
therapy was administered to these 975 patients (551 with
adenocarcinoma, 102 with squamous cell carcinoma, 49 with
ASC, 67 with other histologies).
Of the 49 ASC patients enrolled in the clinical study of TKI
treatment, there were 26 males and 23 females. The perfor-
mance status (PS) was 0e1 in 40 patients (81.6%) and PS 2-3
accounted for 18.4%. The median age of the patients was 56
years (range 40e76 years). Twenty-one of them were in
advanced stage on presentation and 28 presented with a dis-
ease recurrence. Thirteen patients had a history of smoking.
Thirty-eight patients received TKI treatment in the second-line
and 11 in the third-line or further-line treatment. Thirty-one
patients received gefitinib and 18 received erlotinib treat-
ment. The patients’ baseline characteristics are listed in
Table 1.3.2. EGFR mutation analysisTwenty-one patients provided tumor samples for EGFR
mutation analysis out of a total of 49 ASC patients (9 female
and 12 male). EGFR mutations were identified in seven (30%)
patients (4 with deletion in exon 19 and 3 with L858R in exon
21). EGFR mutations occurred significantly more frequently
in women (4/9, 44.4%) than men (3/12, 25%) ( p ¼ 0.64).
Patients who had never smoked (6/15, 40%) had EGFR mu-
tations more commonly than smokers (1/6, 16.7%) ( p ¼ 0.61).
One hundred and ninety-two patients provided tumor samples
for EGFR mutation analysis in adenocarcinoma. EGFR mu-
tations were identified in 58 (30.2%) patients. The EGFR
mutations were identified in four patients among 74 SCC
tumor samples (4/74, 5.41% ). There was a significant dif-
ference among the ASC, adenocarcinoma, and SCC patients in
EGFR mutation frequency ( p < 0.001).3.3. Efficacy and comparison among adenocarcinoma,
SCC, and ASCAmong the 49 ASC patients, 13 had PR and 19 patients had
SD in the gefitinib or erlotinib treatment, accounting for a
disease control rate of 65.3% (32/49). The median PFS during
Fig. 1. Progression-free survival in ASC, adenocarcinoma and SCC patients
( p ¼ 0.047).
wild-type
mutation
wild-censored
Table 1
Comparison of baseline characteristics and efficacy between the ASC,
adenocarcinoma, and SCC treatments.
Variables ASC
(n ¼ 49)
Adenocarcinoma
(n ¼ 512)
SCC
(n ¼ 102)
p
Gender
Male 26 262 74 <0.001
Female 23 250 28
PS
0e1 40 394 83 0.502
2e3 9 118 19
Age (y)
<65 39 410 80 0.930
65 10 102 22
Smoking
Yes 36 352 83 0.034
No 13 160 19
Treatment
Gefitinib 31 291 37 <0.001
Erlotinib 18 221 65
Prior chemotherapy
1 38 334 41 <0.001
2 11 178 61
ORR 26.50% 19.50% 8.80% 0.012
DCR 65.30% 59.60% 36.30% <0.001
Median PFS (mo) 4.3 4.2 1.93 0.047
Median OS (mo) 17.6 18.7 12.2 <0.001
ASC ¼ adenosquamous carcinoma; DCR ¼ disease control rate;
ORR ¼ objective response rate; OS ¼ overall survival; PFS ¼ progression-
free survival; PS ¼ performance status; SCC ¼ squamous cell carcinoma.
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6.1). The median survival time for all patients was 17.6
months (95% CI: 12.1-20.5).
Among the 551 patients with adenocarcinoma who received
gefitinib or erlotinib treatment, 39 received the drug as part of
the first-line treatment and 512 as part of the second-line or
further-line treatment. One hundred and two SCC patients
received TKI treatment. There were significant difference in
PFS among ASC, adenocarcinoma, and SCC treatment
(4.3 months vs. 4.2 months vs.1.93 months, p ¼ 0.047)
(Table 1 and Fig. 1).mutation-censored3.4. The relationship between EGFR mutation and
efficacytime/month
Fig. 2. Progression-free survival of ASC in EGFR mutation patients
( p ¼ 0.013).Among the 49 ASC patients, there were 21 patients with
adequate specimens for EGFR mutation analysis, among the
21 patients, 7 with EGFR mutation and 14 with EGFR wild-
type. Five patients had PR, one had SD, and one had PD in
the patients harboring EGFR mutation. In contrast, the
objective response rate (ORR) was 7.1% (1/14) and DCR was
42.9% (5/14) in the wild-type group. In the 21 ASC patients,
the PFS was 2.1 months and 8.7 months in the wild-type and
mutation groups, respectively ( p ¼ 0.013) (Fig. 2). In 58
adenocarcinoma patients with EGFR mutation, the ORR was
65.5% (38/58) and DCR was 84.5% (49/58). Among the 134
patients with wild-type, the ORR 6.72% (9/134) and DCR
was 36.57% (49/134). The PFS was 2.4 months and 9.4
months in wild-type and mutation group, respectively( p < 0.001). There were only four cases with EGFR mutation
among 74 SCC patients who could provide tumor samples for
EGFR mutation analysis. The ORR was 75% in the mutation
and 5.71% in wild-type patients. The PFS was 7.0 months
and 1.93 months in mutation and wild-type patients,
respectively ( p < 0.001). There were no significant differ-
ence in PFS among the ASC, adenocarcinoma and SCC
patients in the EGFR mutation patients ( p ¼ 0.343) (Fig. 3).3.5. Factors affecting PFS by univariate and
multivariate analysisThe performance status (PS) score was the only factor in-
fluence the PFS ( p ¼ 0.031). No other factors correlated
time/month
Fig. 3. Progression-free survival of ASC, adenocarcinoma and SCC in EGFR
mutation patients ( p ¼ 0.343).
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female and nonsmokers ( p ¼ 0.099 and 0.097, respectively).
A multivariate Cox regression model was constructed
incorporating patient age, sex, PS, smoking history, TKI type
(erlotinib or gefitinib) and prior chemotherapy. PS remained as
the independent prognostic factor for PFS (Table 2).3.6. Toxicity of TKI treatmentToxicity was evaluated in all the 49 patients. The most
common adverse event was skin toxicity in 25 patients
(51.0%), including five patients with Grade 3. Other common
toxicities included diarrhea (12 cases) and fatigue (11 cases).
One patient showed deteriorated hepatic function with erloti-
nib therapy. However, no dosage reduction occurred.
4. Discussion
ASC is an uncommon lung cancer. Owing to its rarity, this
disease has received far less attention in its clinical diagnosisTable 2
Cox regression analysis about PFS of ASC patients.
Variables HR 95% confidence
interval
p
Sex 0.498 0.215e1.152 0.670
Age 0.913 0.363e2.294 0.846
PS 3.228 1.277e8.160 0.013
TKI type 2.230 0.861e5.780 0.199
Prior chemotherapy 0.961 0.499e1.852 0.906
Smoking history 0.641 0.230e1.639 0.331
Surgical history 1.576 0.769e2.572 0.898
CI ¼ confidence interval; HR ¼ hazard ratio; PS ¼ performance status;
TKI ¼ tyrosine kinase inhibitor.and prognosis, and few studies have been published about
ASC. In this series of patients with ASC who received gefi-
tinib or erlotinib, the objective response and disease control
rates were 26.5% and 65.3%, respectively, and the overall
median survival duration was 17.6 months. To the best of our
knowledge, this is the first report that focused on the efficacy
of EGFR-TKIs for ASC.
Owing to the low incidence, available data on EGFR mu-
tation status in ASC was very limited. Several cases of ASC
showing EGFR mutations have been reported with an EGFR
mutation frequency of about 30-44%,12e15 which indicated
that the mutation incidence is similar to adenocarcinoma. The
female, nonsmokers had a high frequency EGFR mutation in
Kang’s report with 25 Korean patients, which was confirmed
by Sasaki et al and Toyooka et al.12e14 However, the EGFR
mutation was not associated with gender, age, and smoking
history in Jia’s report ,which included 55 Chinese ASC pa-
tients.15 Among the 21 patients in our data, there were seven
patients with EGFR mutation. The female, nonsmoking pa-
tients had a high frequency of EGFR mutation.
Owing to the rarity of this subtype carcinoma, the efficacy
of ASC with TKI was not well known until now. Seven cases
of ASC showing EGFR mutations have been reported.16,17 A
pooled analysis by Shukuya et al included three patients of
ASC with EGFR mutation, with all three patients with L858R
mutation in exon 21. Two of the patients reached SD, and one
had PR with gefitinib treatment.18
For Asian patients with adenocarcinoma who received gefi-
tinib or erlotinib in the second- or third-line treatment, the PFS
was ranged from 3 months to 5 months.19 However, the treat-
ment efficacy is much lower in patients with squamous lung
cancer. In the current study, the PFS of ASC was 4.3 months,
which was similar to the adenocarcinoma. For the mutation
patients, the PFS was about 9 months with the TKI therapy in
adenocarcinoma. The median PFS in our seven patients was 8.7
months, which is also similar to the previous studies.
The major limitation of the present study is its retrospective
nature. In addition, direct sequencing was used to analyze the
EGFR mutations in our patients. It has a lower sensitivity than
the amplification refractory mutation system (ARMS), which
may increase the false-negatives in the EGFR mutation result.
Less than half of our patients had EGFR mutation information,
which also influenced our clinical analysis. However, with few
cases even in limited clinical trials, our retrospective study can
also be considered to be meaningful.
In conclusion, a significant proportion of ASC patients
would derive clinical benefit from TKI treatment. A similar
mutation frequency was found in ASC and in adenocarcinoma.
Prospective studies with a larger cohort should be conducted to
verify the efficacy of TKI in ASC patients and mutation
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